IN8bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Aug 10, 2023
NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced financial results and operational highlights for the second quarter ended June 30, 2023. In addition, the Company provided an overview of recent corporate developments through August 2023.
Read more at globenewswire.com
